To date, SmartZyme’s platform has
been used successfully to create a next-generation glucose-sensing enzyme with
a breakthrough mechanism of action, allowing for excellent specificity. SmartZyme
then integrated its novel enzyme into a continuous glucose sensor, which has been
studied preclinically and is on a path to revolutionize diabetes glucose
management. SmartZyme’s second pipeline candidate is a recombinant Factor VII protein
with a very narrow half-life – supported by a pharmacokinetic study in animals –
to treat severe acute bleeding. Neuropathy is SmartZyme's third target, which we plan to treat through the delivery of mRNA encoding for nerve growth factor.